Blockade of VEGF-C/D or VEGF-A delays FITC-LPS from the inflammation site to DLNs in the inflamed skin. AdsVEGFR-3 (R3) or Ad-βgal (109 pfu) was injected 12 hours before the intradermal injection of FITC-LPS into ear skin. VEGF-Trap (25 mg/kg) or dimeric-Fc (Fc, 25 mg/kg) was given 1 day before and after FITC-LPS into ear skin. (A-D) At days 0, 1, and 3 after the injection of FITC-LPS, the remaining FITC-LPS was quantified with IVIS and presented as relative radiance (photons/sec per cm2/steradian). All dots represent mean ± SD from 4 to 5 mice. *P < .05 versus Ad-βgal or Fc. (E) At day 3 after the intradermal injection of FITC-LPS, the ears were sectioned and immunostained for LYVE-1, and merged. Scale bars represent 50 μm. Four independent experiments show similar results.
